FRONTIER BIOTECHNOLOGIES Inc.
Frontier Biotechnologies Inc. (“Frontier Biotech”) is a research-based, commercial-stage, publicly-traded biopharma company dedicated in the discovery, development, manufacture and commercialization of innovative medicines. Frontier Biotech is a 20-year young and ~500-people strong company founded by a group of US-trained scientists, had the first product approval in China in 2018, and went public on Shanghai Stock Exchange in 2020.
Frontier Biotech has developed China’s first new anti-HIV drug called Aikening, aka Albuvirtide, which is also the first long-acting injectable HIV fusion inhibitor in the world. Our built a science-based commercial team to promote Aikening in China and 5 emerging markets, with broad coverage of hospitals and DTP pharmacies, track record in getting Aikening into Chinese National Reimbursement Drug List and Guidelines.
At the same time, Frontier Biotech has built a rich pipeline at various development stages in antiviral (HIV, Covid-19 and HBV), osteoporosis, pain management and hyperlipidemia. Our also built three state-of-the-art manufacturing facilities for APIs and finished products of Lyophilization / liquid fill/finish and packaging lines.
Nanjing: company headquarter, GMP manufacturing facility for peptide API and finished productsChongqing: R&D and marketingBeijing: Center for clinical research, regulatory, government affairs, mar
Frontier Biotech has established an extraordinarilytalented R&D teamwith deep expertise and extensive experience in all aspects of new drug development. Successful development and launch of Aikening ® have enabled Frontier Biotech to develop a state-of-the-art platform for the advancement of long-acting peptide drug innovation, which in turn lays a solid foundation for expandingour product portfolio and further strengtheningFrontier's global competence.